Nafcillin
Nallpen (nafcillin) is a small molecule pharmaceutical. Nafcillin was first approved as Unipen on 1982-01-01. It is used to treat bacterial endocarditis, bacterial infections, bacterial meningitis, bacterial skin diseases, and cellulitis amongst others in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Nallpen (generic drugs available since 2011-04-20, discontinued: Unipen)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nafcillin sodium
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
NALLPEN IN PLASTIC CONTAINER | Baxter | N-050655 RX | 1989-10-31 | 2 products, RLD, RS |
Show 6 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
nafcillin | ANDA | 2023-02-14 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
bacterial endocarditis | EFO_1000830 | D004697 | — |
bacterial infections | — | D001424 | A49 |
bacterial meningitis | EFO_1000831 | D016920 | G00 |
bacterial skin diseases | — | D017192 | — |
cellulitis | EFO_0003035 | D002481 | L03.90 |
osteomyelitis | EFO_0003102 | D010019 | M86 |
postoperative complications | — | D011183 | — |
respiratory tract infections | — | D012141 | J06.9 |
staphylococcal infections | — | D013203 | A49.01 |
urinary tract infections | EFO_0003103 | D014552 | N39.0 |
Show 1 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
---|---|
S0032 | Injection, nafcillin sodium, 2 grams |
Clinical
Clinical Trials
1 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neonatal sepsis | D000071074 | HP_0040187 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | NAFCILLIN |
INN | nafcillin |
Description | Nafcillin is a penicillin in which the substituent at position 6 of the penam ring is a (2-ethoxy-1-naphthoyl)amino group. It has a role as an antibacterial drug. It is a penicillin and a penicillin allergen. It is a conjugate acid of a nafcillin(1-). |
Classification | Small molecule |
Drug class | penicillins |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCOc1ccc2ccccc2c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12 |
Identifiers
PDB | — |
CAS-ID | 147-52-4 |
RxCUI | 7233 |
ChEMBL ID | CHEMBL1443 |
ChEBI ID | 7447 |
PubChem CID | 8982 |
DrugBank | DB00607 |
UNII ID | 4CNZ27M7RV (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,061 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
20 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more